Back to Journal

SM Vaccines and Vaccination Journal

Pharmacist as Immunization Provider in Manitoba, Canada

Abstract Citation Introduction Methods Results Discussion References
Details

Received: 18-Feb-2016

Accepted: 29-Mar-2016

Published: 30-Mar-2016

Yichun Wei1*, Songul Bozat-Emre1,2, Inga Hossack1 and Tim Hilderman1,2

1Manitoba Health, Healthy Living and Seniors, Canada

2Faculty of Health Sciences, University of Manitoba, Canada

Corresponding Author:

Yichun Wei, Epidemiology &

Surveillance, Manitoba Health, Healthy

Living and Seniors, Canada

Keywords

Pharmacist; Immunization; Influenza; Vaccine; Manitoba; Canada; 2014

Abstract

Background: In 2014, Manitoba introduced legislation authorizing pharmacists to administer four publicly funded vaccines to patients seven years of age and older. As part of an expanded scope of practice initiative, pharmacists could administer the Human Papilloma Virus (HPV) vaccine, Tetanus-diphtheria-acellular pertussis (Tdap) vaccine, Pneumococcal Polysaccharide (PPV23) vaccine, and seasonal influenza (FLU) vaccine. Pharmacists began administering the four vaccines as of September 1, 2014, three weeks before the influenza immunization campaign began. This study assesses the initial impact that pharmacists had on the population uptake of the seasonal influenza vaccine as well as the other three publicly funded vaccines.

Methods: The data for this study were obtained from Manitoba Immunization Monitoring System (MIMS), the population-based and province-wide immunization registry. We analyzed immunizations of the four publicly funded vaccines administered by all immunization providers in Manitoba during two periods: September 1, 2013 to January 31, 2014 (2013-2014) and September 1, 2014 to January 31, 2015 (2014-2015).

Results: Between September 1, 2014 and January 31, 2015, within the first few months after pharmacists in Manitoba began immunizing patients, they administered 44,220 doses of HPV, Tdap, PPV23 and FLU in total. They contributed significantly to the FLU immunization program, and were the third largest provider, especially for urban residents and patients aged 45 and older. Overall, they administered 43,638 FLU doses (15% of the provincial total). The number of FLU immunizations provided by physicians decreased by 32,573 doses; however, physicians administered more immunizations to the six months to five years age group in 2014-2015 (12,445) than in 2013-2014 (11,969).

Conclusion: Pharmacists’ participation in Manitoba’s publicly funded immunization program has been well accepted in Manitoba. However, the provider expansion did not increase the uptake of the FLU vaccine in the 2014-2015 season. Regardless, the participation of pharmacists in the provincial immunization program increases access to immunizations, and could reduce pressure on other primary care providers. This could potentially decrease wait times and increase availability of appointments for patients with more serious medical issues. Further studies are required.

Citation

Wei Y, Bozat-Emre S, Hossack I and Hilderman T. Pharmacist as Immunization Provider in Manitoba: Canada. SM Vaccine Vaccin. 2016; 2(1): 1016.

Introduction

Influenza viruses circulate around the world. They cause infections and complications, and are associated with significant morbidity and mortality. The World Health Organization (WHO) has estimated that around one billion seasonal influenza infections occur each year, with around 3-5 million cases of severe illness, and 300,000-500,000 deaths [1]. The burden of influenza on society is significant. In the United States, cost estimates resulting from influenza have been reported to be over $10.4 billion a year for direct medical costs and $87.1 billion in total annual economic burden [2]. In Canada, influenza and pneumonia together are ranked as the eighth leading cause of death [3]. During each influenza season, approximately 12,200 hospitalizations and 3,500 deaths are associated with influenza infections in Canada [4]. The severe illness most often occurs among young children (65 years), and people with high-risk medical conditions [5,6].

Immunization against influenza serves as the primary public health intervention for both prevention and control [7]. The National Advisory Committee on Immunizations (NACI), a Canadian national committee of experts, recommends that all Canadians six months of age and older be immunized every year [8]. Success of the influenza vaccination program requires a high coverage rate. In Canada, the influenza vaccine coverage rate is relatively high and it is increasing according to the Canadian Community Health Survey. Within the 12 months prior to responding to the survey, nearly a third of Canadians over the age of 12 years were immunized in the 2013-2014 season [9]. However, the coverage rate was still below the NACI target of 80%, especially among two high risk groups: 64% among those over 65 years and 32% among those under 65 years with one or more chronic conditions (heart disease, effects of stroke, asthma, diabetes, cancer, emphysema, bronchitis, chronic obstructive pulmonary disease and obesity at a high level).

To increase access to immunizations, over the last few years, pharmacists’ practice has been expanded to include the administration of vaccines across Canada. In provinces that have implemented this practice, the publicly funded influenza vaccine has been accessible from pharmacists. The minimum age that pharmacists are authorized to immunize differs between provinces, typically ranging between 5 and 9 years. The addition of pharmacists as immunization service providers is expected to create multiple immunization access points, provide flexible access to services through extended hours and days of the week, and remove barriers to immunization. For example, rural and northern pharmacies can provide additional locations to underserviced and remote communities. This expansion of practice could also bring other benefits to primary care delivery by reducing the pressure on physicians and nurse practitioners. Reduced patient contact time devoted to immunizations could allow these primary care providers to see patients with more serious medical conditions.

Pharmacist-administered immunization has become well accepted by patients and will probably increase vaccination rates [10 13]. In the 2009-2010 influenza season, when pharmacists were first given the authority to administer injections to residents in British Columbia, they only administered 30,000 doses of the influenza vaccine. In the 2014-2015 influenza season, pharmacists administered nearly half a million doses [14]. After Ontario pharmacists were given the authority to administer influenza vaccines in 2012, they administered 247,000 doses in the first year [15] and more than 765,000 in the second year [16]. A study in the United States suggests that higher immunization rates are present in states where pharmacists can administer vaccines [17]. Additionally, surveys indicate that the satisfaction of pharmacist-administered immunizations is high [18].

Pharmacists might have been preferred over physicians and public health nurses. In Alberta, it was reported that pharmacies were about to outpace public health clinics for influenza immunization. According to Alberta Health, in the 2010-2011 season, only 45,353 influenza immunizations were received in pharmacies compared to 528,753 in public health clinics. However, in the 2014-2015 season, 485,669 immunizations were received in pharmacies, similar to the number, 496,220, in public health clinics [19]. The increased access and extended hours provided by over 1,000 pharmacies compared with around 200 public health clinics probably contributed the most to this trend.

On January 1, 2014, Manitoba introduced legislation under the Manitoba Pharmaceutical Act that authorizes certified pharmacists to administer immunizations to patients seven years of age and older including four publicly funded vaccines: Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular pertussis (Tdap), Pneumococcal Polysaccharide (PPV23), and seasonal influenza (FLU). Manitoba has offered publicly funded influenza vaccines to all Manitobans six months of age and older since 2010. It was expected that this addition of pharmacists as immunization providers would increase public access to immunization services for all Manitobans and increase population coverage. After implementing safety measures, inventory management, distribution logistics, and reporting mechanisms, qualified pharmacists began administering publicly funded vaccines on September 1, 2014, three weeks before the regular influenza immunization campaign began. They were required to report all immunizations to the provincial immunization registry, Manitoba Immunization Monitoring System (MIMS).

To evaluate the acceptability of pharmacist-administered immunizations and the impact on the uptake of vaccines, especially FLU, in February 2015, a study was conducted for the Provincial Vaccine Advisory Committee of Manitoba using data from MIMS. In this study, the immunizations of the four publicly funded vaccines (HPV, Tdap, PPV23, and FLU) administered by all providers including pharmacists before and after the program expansion were analyzed. It was anticipated that the addition of pharmacists as immunization service providers would be well accepted in Manitoba. In addition, we hypothesized that pharmacists would increase vaccine uptake, especially the uptake of the FLU vaccine, among residents in the province.

Methods

Data for this study were extracted from MIMS, the population based and province-wide immunization registry that has been implemented since 1988. MIMS provides monitoring and reminders to help ensure that recommended immunizations are received [20]. Information pertaining to all immunizations administered to Manitobans who are registered for health services in the province is entered into this system including the type of vaccine administered, service date, and provider information. The use of MIMS data for monitoring, evaluation, and research purposes has been explained in a number of studies [21-24].

In this study, the four publicly funded vaccines that pharmacists were authorized to administer were analyzed: FLU, HPV, PPV23, and Tdap. For comparison, the immunizations administered during two time periods were analyzed: September 1, 2013 to January 31, 2014 (2013-2014) and September 1, 2014 to January 31, 2015 (2014-2015). Service providers considered in this report included public health nurses, physicians, pharmacists, and others. The other category included all other types of providers reported in MIMS, such as publicly funded health facilities (usually a hospital), private health care providers, occupational health providers, and unknown providers.

Results

Overall

Immunizations for the four vaccines are reported in Table 1. A total of 335,358 doses in 2013-2014 and 316,457 doses in 2014-2015 for the four vaccines were delivered by all providers. During both periods, over 85% of the service was for FLU.

Table 1: Immunization by provider type, 2013-2014 and 2014-2015, Manitoba.

 

 

Public Health Nurse

Physician

Pharmacist

Other

Total

Vaccine

Period

Doses

(%)

Doses

(%)

Doses

(%)

Doses

(%)

Doses

FLU

2013-2014

2014-2015

123,335

109,360

(41.8)

(38.7)

139,354

106,781

(47.3)

(37.8)

13

43,638

(0.0)

(15.5)

32,252

22,686

(10.9)

(8.0)

294,954

282,465

HPV

2013-2014

2014-2015

10,548

8,219

(66.8)

(76.2)

4,685

2,310

(29.7)

(21.4)

<5

32

(0.0)

(0.3)

<500

232

(3.5)

(2.2)

15,783

10,793

PPV23

2013-2014

2014-2015

3,706

3,217

(35.4)

(33.7)

6,099

5,197

(58.2)

(54.5)

0

450

(0.0)

(4.7)

670

677

(6.4)

(7.1)

10,475

9,541

Tdap

2013-2014

2014-2015

5,880

5,306

(41.6)

(38.9)

5,610

5,826

(39.7)

(42.7)

0

100

(0.0)

(0.7)

2,656

2,426

(18.8)

(17.8)

14,146

13,658

Total

2013-2014

2014-2015

143,469

126,102

(42.8)

(39.8)

155,748

120,114

(46.4)

(38.0)

14

44,220

(0.0)

(14.0)

36,127

26,021

(10.8)

(8.2)

335,358

316,457

The fact that there were more HPV immunizations in 2013-2014 (15,783) than in 2014-2015 (10,793) was likely due to the high-risk HPV program implemented between November 2012 and March 2014. This program targeted females aged between 9 and 26 years who were at higher risk for HPV infections. For the school-based HPV program, the number of immunized patients from the target birth cohorts (2002 birth cohort in 2013-2014 vs. 2003 birth cohort in 2014 2015) was similar, over 4,700, during both periods. Most noticeably, the number of FLU immunizations administered decreased by 12,489 from 2013-2014 to 2014-2015. This change was probably due to a spike in demand in 2013-2014 from a perceived supply shortage and the increased influenza A (H1N1) incidence across Canada.

HPV, PPV23, and Tdap immunizations by provider type

For the immunization of HPV, PPV23, and Tdap, public health nurses and physicians were the two major service providers (Table 1). Together, they delivered over 95% of the HPV immunizations, 90% of the PPV23 immunizations, and 80% of the Tdap immunizations during both study periods.

The addition of pharmacists in the late fall of 2014 had little impact on the immunization of HPV and Tdap (32 doses for HPV and 100 doses for Tdap). This is not unexpected. The HPV vaccine is mostly administered as part of the school immunization program (Grade 6) by public health nurses. The Tdap vaccine is mostly provided by physicians to young children below the age of seven or administered as part of the school immunization program (Grade 8/9).

There were a small number of PPV23 immunizations (450) administered by pharmacists in 2014-2015, accounting for almost 5% of the total doses administered. Once Manitobans turn 65, they become eligible for one dose of PPV23. Letters of eligibility are sent to all Manitobans who turned 65 in the previous year and who have not already received a dose of PPV23. This mail out is conducted in parallel with the influenza season. In previous years, the letters advised people to contact their physicians while in 2014-2015, the letter included pharmacists as well.

FLU immunization by provider type

Public health nurses and physicians were major providers of the FLU immunization during both 2013-2014 and 2014-2015. Pharmacists also administered a significant number of FLU doses in the first year they were authorized to administer this publicly funded vaccine. In 2013-2014, public health nurses and physicians administered nearly 90% of the total FLU immunizations. In 2014 2015, they administered just over 75% and pharmacists administered over 15% (Figure 1).

Figure 1: FLU immunization by provider type, 2013-2014 and 2014-2015, Manitoba.

In 2014-2015, physicians and public health nurses both administered fewer FLU doses than in 2013-2014. The number of physician-administered immunizations decreased by 32,573 (106,781 in 2014-2015 vs. 139,354 in 2013-2014). Public health nurse administered doses decreased less. However, decreases in physician- and public health nurse-administered doses were largely offset by the pharmacist-administered doses.

FLU immunization by patient residency

More than 60% of Manitoba residents are concentrated in Manitoba’s capital, Winnipeg, and the second largest city, Brandon. In this study, Winnipeg and Brandon were defined as urban and all other communities were defined as rural [25-27]. The FLU immunizations received by residents from rural and urban areas and administered by different service providers in 2013-2014 and 2014 2015 are presented in Figure 2.

Figure 2: FLU immunization by patient residency and provider type, 2013 2014 and 2014–2015, Manitoba.

Residents in rural areas rely on public health nurses’ provision of immunizations. During both study periods, public health nurses administered approximately 70% of the immunizations to residents in rural areas. Residents in urban areas, however, rely mostly on physicians. In 2013-2014, physicians administered 61% of all immunizations to residents in urban areas, but, in 2014-2015, they only administered 48% of all immunizations to urban residents. During this period, pharmacists administered 35,501 immunizations to urban residents, which accounted for nearly 19% of the FLU doses urban residents received. In comparison, in rural areas, pharmacists administered less than 9% of the doses.

FLU immunization by month

The FLU immunizations administered by different service providers by month in 2013-2014 and 2014-2015 are presented in Figure 3. In Manitoba, the annual influenza immunization campaign normally launches in the third week of September. Accordingly, most FLU doses were administered in October and November during both study periods.

Figure 3: FLU immunization by provider type and month, 2013-2014 and 2014-2015, Manitoba.

In January 2015, only 5,491 FLU doses were administered, a decrease of almost 23,000 from January 2014, which probably contributed to the overall decrease in the FLU uptake in 2014-2015. The difference was most likely due to a surge in demand for FLU in January 2014 that Manitoba and every province/territory experienced as a result of a perception of limited FLU supply and concerns over the circulating influenza A (H1N1) strain. In January 2015, the demand for FLU returned to the similar level as in previous four seasons.

In either 2013-2014 or 2014-2015, the monthly immunizations of FLU were different among different service providers. Public health nurses administered a similar number of doses in October of 2013 and 2014, 83,955 and 80,205 doses respectively, which accounted for 70% of their total service. They also administered a smaller and similar number of doses in November of 2013 and 2014, 22,382 and 24,640 respectively. Public health nurses run their mass FLU immunization clinics during these months each year. Physicians administered different amounts in October and November, which also varied between 2013 and 2014. Compared with 2013, physicians delivered almost 39,000 fewer doses in October 2014 but 13,000 more in November 2014. Pharmacists administered the FLU doses predominantly in October and November in 2014, around 20,000 in each month. There were delays in the delivery of FLU vaccines from manufacturers in the 2014-2015 season. This is probably the reason that more FLU immunizations were administered in November and December of 2014 compared with 2013.

FLU immunization by patient age group

Further analysis of the FLU uptake was conducted to investigate which age groups were served by pharmacists. The FLU immunizations by different service providers among different age groups of patients in 2014-2015 were compared to those in 2013-2014 (Figure 4).

Figure 4: FLU immunization by patient age group and provider type, 2013–2014 and 2014–2015, Manitoba.

As expected, public health nurses and physicians were the major immunization providers for all age groups during both study periods. Since September 2014, pharmacists also contributed significantly to the FLU immunization among all age groups except young children six months to five years of age. This was expected since pharmacists are only permitted to immunize patients at least seven years of age. Over 70% of pharmacist-administered FLU immunizations were to people aged 45 years and older. Among that age group, almost 17% of the uptake was administered by pharmacists. Over this period, public health nurses and physicians decreased their immunization service in almost every age group. Most noticeably, physicians administered 28,129 immunizations to the 45-64 age group in 2014-2015, a decrease of over 11,000 from one year prior (39,352). There was one exception. Physicians delivered nearly 500 more immunizations among the six months to five years age group in 2014-2015 (12,445) than in 2013 2014 (11,969).

Discussion

In this study, we found that pharmacists have been accepted as immunization providers in Manitoba. Within the first few months after pharmacists began immunizing people, they administered a significant number of immunizations, mostly for the seasonal influenza vaccine. They were an important service provider of influenza immunizations among all Manitoba residents seven years of age and older, especially among those aged 45 and older, and those from urban areas. Overall, they administered over 15% of the total influenza immunizations in Manitoba between September 1, 2014 and January 31, 2015.

The vaccine uptake in 2014-2015, especially the influenza vaccine, did not increase from 2013-2014 despite the additional service provided by pharmacists according to the coverage rate by end of the 2013-2014 and 2014-2015 influenza season [28,29]. There were a number of contributing factors. First, doses administered in January 2014 exceeded the normal number in previous Januaries. In January 2014, Manitoba and every other province/territory in Canada experienced a surge in demand for the influenza vaccine, partially due to a perception of limited supply of the vaccine and public concerns over the circulating influenza A (H1N1) strain. In January 2015, the demand for the influenza vaccine returned to the level in previous seasons. Second, lower vaccine effectiveness was expected earlier in the season due to the antigenic shifting in the circulating influenza strain. Subsequently, interim estimates of the effectiveness of the 2014-2015 influenza vaccine in January 2015 were reported to be virtually zero in Canada and 23% in the United States in comparison to 70% in 2013-2014 [30-33]. This might have had a negative impact on the uptake of the influenza vaccine in the 2014-2015 season.

More possibly, the study period was within the first five months after pharmacists began the immunization service. Not many pharmacists were certified to provide the service and the public may not have been fully aware of the immunization service available from pharmacists. In other provinces, increasing uptake of the influenza vaccine from pharmacists continued to be observed after the first year they were authorized to immunize patients. In Manitoba, preliminary immunization data in the 2015-2016 influenza season indicate that there were more pharmacist-administered immunizations than in 2014-2015. In addition, a higher percentage of patients immunized by pharmacists in 2014-2015 had never been previously immunized compared to those immunized by physicians and public health nurses. Continuous surveillance of immunization is necessary to evaluate the acceptability of immunizations by pharmacists and to identify barriers from the perspectives of both patients and pharmacists [34,35].

The main advantage for pharmacist-administered immunizations is convenience [36,37]. As of November 2013, there were almost 350 pharmacies in Manitoba. Many pharmacies are open 7 days a week with longer hours than most medical clinics. Patients can drop in rather than setting up an appointment to be immunized. Besides, pharmacies are often close to residential neighborhoods and there is a high visibility of this service in the community setting. More importantly, over 130 pharmacies are located outside Winnipeg, serving populations in rural and northern areas, which has the potential to increase accessibility to underserviced and remote communities. Within the first few months after pharmacists began immunizing patients, less than 20% of the pharmacist-administered influenza immunizations were delivered to residents in rural areas, which accounted for less than 9% of the total in rural areas in comparison to 19% in urban areas. This recommends that the acceptability of pharmacist-administered immunizations in rural areas has not been as high as in urban areas. There is a potential for improvement. Barriers to access the immunization service by pharmacists particularly in rural areas should be further investigated.

Adding pharmacists as immunization providers could benefit primary care delivery by reducing some pressure on other care providers. This might positively impact wait times and availability for patients with serious health issues. We found that physicians immunized 500 more young children in 2014-2015 than in 2013 2014, children that pharmacists were not authorized to immunize. Further analysis of the shift of service providers and the potential impact on improving primary care service delivery in Manitoba is required.

There are a few limitations in this study. First, only immunizations between September 2014 and January 2015 were included, while an influenza immunization season usually continues till the end of March. Compared to the total influenza immunizations between September 1, 2014 and March 31, 2015 in Manitoba, nearly 15,000 doses in February and March 2015 were not included in this study [28]. Second, pharmacists began administering publicly funded immunizations in September 2014, just before the influenza immunization campaign began. Therefore, the general public was mostly unaware of the other three vaccines that pharmacists were also authorized to administer. Immunizations of the other publicly funded vaccines by pharmacists should be further evaluated when more data become available.

The practice of pharmacists has been expanded to include immunizing people to improve vaccine coverage. As of October 2014, certified pharmacists in many provinces, British Columbia, Alberta, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador, were authorized to administer immunizations [38]. Pharmacists in Saskatchewan began vaccinating people in October 2015 [39]. In provinces with available data, pharmacist-administered influenza immunizations seem to be well accepted by the public.

Recently, in a few provinces, pharmacists have been authorized to provide other vaccines. In British Columbia, since February 2013, pharmacists can administer publicly funded vaccines such as Tetanus-diphtheria (Td), Measles-Mumps-Rubella (MMR), HPV Cervarix, Influenza and Pneumococcal Polysaccharide, Hepatitis A and B, HPV-Gardasil, Meningococcal-C, and Tetanus, diphtheria and acellular pertussis (Tdap) among several others by special request [40]. Ontario is also considering expanding the vaccines pharmacists can administer [41]. With the improved accessibility and reduced barriers, it is expected that vaccine coverage will be increased, contributing to the continuous prevention and control of a number of vaccine preventable diseases. Hopefully, pharmacists’ provision of immunizations will also bring noticeable benefits to the other perspectives of the primary care system.

References

1. World Health Organization. Influenza (Seasonal) Fact sheet N°211. 2014.

2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25: 5086-5096.

3. Statistics Canada. The 10 leading causes of death. 2011.

4. Public Health Agency of Canada. Public Health Reminder: Seasonal Flu.

5. Schanzer DL, Tam TW, Langley JM, Winchester BT. Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect. 2007; 135: 1109-1116.

6. Public Health Agency of Canada. An Advisory Committee Statement (ACS)-National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015-2016.

7. Webster RG, Monto AS, Braciale TJ, Lamb RA. Textbook of Influenza. Wiley.2013.

8. Public Health Agency of Canada. National Advisory Committee on Immunization (NACI).

9. Statistics Canada. Flu vaccination rates in Canada.

10. Francis M. and Hinchliffe A. Vaccination services through community pharmacy: a literature review. Wales PH. 2010.

11. The Pharmaceutical Society of Ireland, Seasonal influenza vaccination programme in pharmacies-evidence base and framework. Dublin (Ireland). 2011.

12. Isenor JE, Alia TA, Killen JL, Billard BA, Halperin BA, Slayter KL, et al. Impact of pharmacists as immunizers on influenza vaccination coverage in Nova Scotia, Canada. Hum Vaccin Immunother. 2016.

13. MacDougall D, Halperin BA, Isenor J, Cameron DMK, Li L, McNeil SA, et al. Routine immunization of adults by pharmacists: attitudes and beliefs of the Canadian public and health care providers. Hum Vaccin Immunother. 2016.

14. British Columbia Pharmacy Association. Seasonal Flu Info: Pharmacies an increasingly popular option for flu shots.

15. Ontario Government. Tough Decisions, Made Responsibly, Ontario Public Drug Programs Annual Report. 2012-2013.

16. Ontario Government. Progress Report 2014: health care.

17. Steyer TE, Ragucci KR, Pearson WS, Mainous AG. The role of pharmacists in the delivery of influenza vaccinations. Vaccine. 2004; 22: 1001-1006.

18. Poulose S, Cheriyan E, Cheriyan R, Weeratunga D, Adham M, et al. Pharmacist-administered influenza vaccine in a community pharmacy: A patient experience survey. Can Pharm J. 2015; 148: 64-67.

19. Simes J. Alberta pharmacies starting to outpace public health clinics for flu shots, in Metro Calgary. 2015.

20. Roos LL, Fedson DS, Roberts JD, Cohen MM, et al. Reminding and monitoring: new uses of administrative data for preventive care. Healthc Manage Forum. 1996; 9: 30-36.

21. Gupta S, Roos LL, Walld R, Traverse D, Dahl M. Delivering equitable care: comparing preventive services in Manitoba. Am J Public Health. 2003; 93: 2086-2092.

22. Katz A, Soodeen RA, Bogdanovic B, De Coster C, Chateau D. Can the quality of care in family practice be measured using administrative data? Health Serv Res. 2006; 41: 2238-2254.

23. Mahmud SM, Bozat-Emre S, Hammond G. Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic? PLoS One. 2015; 10: e0142754.

24. Roberts JD, Poffenroth LA, Roos LL, Bebchuk JD, Carter AO. Monitoring childhood immunizations: a Canadian approach. Am J Public Health. 1994; 84: 1666-1668.

25. Kozyrskyj A, Lix L, Dahl M, Soodeen RA. High-cost Users of Pharmaceuticals: Who are they? Manitoba Centre for Health Policy. 2005.

26. Kozyrskyj A, Currie RJ. Effects of Manitoba Pharmacare Formulary Policy on Utilization of Prescription Medications. Manitoba Centre for Health Policy. 2009.

27. Martens P, Fransoo R, Coster CD, McKeen N, Ekuma O, Prior H, et al. Patterns of Regional Mental Illness Disorder Diagnoses and Service Use in Manitoba: A Population-Based Study. Manitoba Centre for Health Policy. 2004.

28. Government of Manitoba, Annual Influenza Report, 2014-2015, Manitoba Health Healthy Living and seniors. 2015.

29. Government of Manitoba, Annual Influenza Report, 2013-2014, Manitoba Health Healthy Living and seniors. 2014.

30. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A (H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015; 20.

31. Centers for Disease Control and Prevention. CDC Presents Updated Estimates of Flu Vaccine Effectiveness for the 2014-2015 Season. 2015.

32. Bozat-Emre S. A review of mid-season effectiveness of the 2013/14 seasonal influenza vaccines. 2015.

33. Bozat-Emre S. Effectiveness of seasonal influenza vaccines against influenza A (H1N1) infection in post-pandemic seasons: Highlights of a systematic review. 2015.

34. MacDougall DM, Halperin BA, MacKinnon-Cameron D, Li L, McNeil SA, Langley JM, et al. The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. BMJ Open. 2015; 5: e009062.

35. Edwards N, Gorman Corsten E, Kiberd M, Bowles S, Isenor J, Slayter K, et al, Pharmacists as immunizers: a survey of community pharmacists’ willingness to administer adult immunizations. Int J Clin Pharm, 2015; 37: 292-295.

36. Anderson C, Thornley T. Who uses pharmacy for flu vaccinations? Population profiling through a UK pharmacy chain. Int J Clin Pharm. 2016.

37. Anderson C, Thornley T. “It’s easier in pharmacy”: why some patients prefer to pay for flu jabs rather than use the National Health Service. BMC Health Serv Res. 2014; 14: 35.

38. Canadian Pharmacists Association. Pharmacist’s Role in Flu Vaccination.

39. Pharmacy Association of Saskatchewan. Flu Shots 2015-2016.

40. British Columbia Pharmacy Association. Administration of Injections.

41. Brennan RJ. Ontario may allow pharmacists to give variety of vaccines. Queen’s Park. 2015.

Other Articles

Article Image 1

Dengue Virus Infection: Current Challenges and Future Perspectives

Dengue infection is a zoonotic disease caused by Dengue virus, a single-strand RNA flavivirus. It is transmitted to humans through primarily Aedes aegypti (mosquito) bites. The disease prevalence is higher in tropical zones where there are high humidity and temperature as well as unplanned urbanization. According to the WHO, more than 100 tropical countries are afflicted by Dengue infection, leading to severe economic impact. Brazil is currently a major hotspot of Dengue infection. The number of infected people with dengue virus increased 240% in the first trimester of 2015 compared to the same period last year, surpassing the WHO estimative. In an attempt to stop the infection from spreading, the Brazilian Health Ministry has increased the budget to nearly $50 million to combat the vector. However, the bureaucracy of the Brazilian government has led to slow release of the allocated money to the affected cities and the results have been catastrophic. To make the situation worse, the slow diagnosis and the subsequent delay in starting the treatment has led to increased mortality rates. Currently, the only treatment available for Dengue infection is supportive, which is not very efficient against the most severe cases such as Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS).

Eduardo L V Silveira1*


Article Image 1

The Brazilian Experience on BCG Immunization and the Development of New Vaccines against Tuberculosis

The interruption of centuries of decline in case rates of Tuberculosis (TB) occurred, in most cases, in the late 1980s and involved industrialized countries due to increased poverty in urban settings and the immigration from TB high-burden countries. Thus, no sustainable control of TB epidemics can be reached in any setting without properly addressing the global epidemic.

A considerable rate of deaths from TB has been attributed to co-infection with Mycobacterium tuberculosis and Human Immunodeficiency Virus (TB-HIV). Immune deficient patients with HIV are at increased risk of latent M. tuberculosis infections (LTBI) progressing to active disease and being transmitted to others represents a considerable reservoir of bacilli. In addition, more than a half of the new TB cases are potentially MDR-TB “super strains” in the hot zones, such as the “BRICS” countries (Brazil, the Russian Federation, India, China and South Africa). MDR-TB strains, an airborne bacterium that is spread just as easily as drug-sensitive TB, are resistant to at least three of the four main drugs used to treat TB. Likewise, it has been reported the emergence of extensively drug-resistant (XDR) TB cases, defined as cases in persons with TB whose isolates are resistant to isoniazid and rifampicin (MDR-TB) as well as resistant to any one of the fluoroquinolone drugs and to at least one of the three injectable second-line drugs, Amikacin, Kanamycin or Capreomycin. XDR-TB is widespread raising the prospect of virtually incurable TB worldwide, such as the novel Total Drug-Resistant (TDR) TB strains found in India, Italy and Iran. The factors that most influence the emergence of drug-resistant strains include inappropriate treatment regimens, and patient noncompliance in completing the prescribed courses of therapy due to the lengthy standard “short-course” treatment or when the side effects become unbearable.

Paulo R Z Antas*


Article Image 1

The Challenges of Vaccine-Preventable Diseases in the 21st Century

Recently, I attended the Modern Vaccines Adjuvants and Delivery Systems conference held in Leiden, The Netherlands (May 18-20, 2015); which highlighted some of the major challenges in the development of efficacious vaccines and their effective delivery for both (re) emerging infectious diseases and endemic Neglected Tropical Diseases (NTDs). These infections include not only the “big three” of Malaria, HIV/AIDS and Tuberculosis, but also Leishmaniasis, Ebola, MERSCOV, helminths and others. Notably, for the “big three” attempts to develop such vaccines have been largely disappointing. Some of the challenges lie with the extreme genetic variability of the pathogens. Most successful vaccines have been against slowly evolving pathogens with a limited number of antigenically different strains that induce immune responses dependent on neutralizing antibodies; a mechanism that is well understood. Also, for most vaccine preventable diseases, natural infections with their pathogens leave the host (temporarily, partially) immune to reinfection or disease with the same (strain of) pathogen. The danger of these pathogens is that they often win the race between their own rapid rate of multiplication and the host response which depends on immune recognition and activation and proliferation of immune cells, specifically-B cells. Once the host mounted an immune response and survived the fight he has won the race. Most of the infections above, however, do not conform to that pattern. In TB, cellular mechanisms are essential for controlling the infection, but do not eliminate it. The pathogens, Mycobacterium tuberculosis (Mtb), reproduce very slowly and disease occurs, if at all (in a minority of infections), months or years after infection. Disease, once cured, does not offer protection against reinfection or disease from reinfection. Speed of immune recognition seems to play no role, as most individuals who develop TB have detectable (by IGRA or TST) immune responses to the pathogens. Rather, it seems, a failure of the cellular effector mechanisms is at fault, and if so the prospects for an effective vaccine that protect against disease are slim. As neutralizing antibodies play no role in protection, also the prospects of conferring protection against (re) infection seem equally poor. Immune mechanisms against malaria and HIV are also complex and poorly understood, and attempts to develop an HIV vaccine have been graphically called “shots in the dark” [1]. The more I learn about vaccines and vaccination, the more I become perplexed, less optimistic, but also fascinated. Despite the stunning recent advances in immunology and medical research why do we still fail, and what are the missing scientific links? Are vaccines for some infections simply impossible, or are we simply not aiming our efforts correctly? Progress seems increasingly difficult, but the rewards of success, therefore so huge. The English physician Edward Jenner developed (or rather discovered) that cowpox offered a relatively safe alternative to the risky practice of variation in 1796 and in 1977 smallpox was eradicated worldwide. On May 8, 1980, the World Health Assembly announced that the world was free of smallpox and recommended that all countries cease vaccination: “The world and all its people have won freedom from smallpox, which was the most devastating disease sweeping in epidemic form through many countries since earliest times, leaving death, blindness and disfigurement in its wake” [2]. Jenner just observed, but knew nothing about viruses, let alone immunology.

Mohamud Sheek-Hussein*1


Article Image 1

Progress Towards Measles Elimination: Oman Experience

The Eastern Mediterranean region has set goals for interrupting indigenous transmission of measles using a strategy developed by the World Health Organization. This strategy includes recommendations for vaccination activities to be achieved and sustained thereby increasing the population’s immunity. Measles epidemiological surveillance systems were developed to monitor illnesses characterized by febrile rash, and to provide effective virus detection and serological surveillance. Elimination is defined as the absence of endemic measles transmission in a defined geographical area (e.g., region or country) for ≥12 months in the presence of a well-performing surveillance system. Oman has committed to these goals.

Measles was a leading cause of infant and child morbidity and mortality in Oman before the introduction of measles vaccine by 1975 and thereafter until 1994. With the introduction of a second dose of measles vaccine in 1994, coverage for first and second doses of measles vaccine increased more than 95% in 1996 and has been sustained at a level greater than >95% since then. A national Measles and Rubella (MR) immunization catch-up campaign targeting children ages 15 months to 18 years was conducted in 1994 that achieved 94% coverage. As a result, the incidence of measles has declined markedly in recent years, to ≤ 1 case per million persons in 2012 and to zero cases in 2013.

Oman has made significant progress toward measles elimination and has met the regional elimination goals. However, new challenges faced by Oman, for instance with increased globalization, has led to issues such as outbreaks from imported cases. Additional challenges still remain with regard to increasing identification and immunization of unvaccinated non-Omani workers and their families.

Salah T Al Awaidy1*, Said Al Baqlani2 , Salim Al Mahrouqi3 , Badder Al Rawahi3 , Suleiman Al Busaidi1 , Idris Al Obaidani3 , Maryam Al Shabibi3 , Hosammudin Mohammed NwarAl Den3 , Adil Mohammed Al Barwani4 , Aisha Said Al Amri and Nadia Teleb5


Article Image 1

Avian Influenza Type A-H5N1 Epidemiological Model: Puerto Rico as a Case Study

Our research focused on Avian Influenza Type A-H5N1, specifically on an epidemiological model centered in Puerto Rico. Our main goal is to address the following: first, to determine the potential outbreaks of this disease in Puerto Rico using as a base the location of the poultry industry as a hub, we are interested in the repercussions of the infection among the human-to-human potential interaction. The second goal centers on the possibility of vaccination to mitigate an epidemic among humans. In order to address these goals and future ones, we will construct a mathematical model and use parameters according to two cases; the first is a single population model and the second one is a metapopulation model involving 5 cities in Puerto Rico. Our research will specifically target the spread of this particular disease, to investigate possible alternatives to mitigate the spread using measures of immunization. Our results show that a 30% vaccination regime will eradicate the disease in cities that are immunized.

Collazo-Rivera M and Cruz-Aponte M*


Article Image 1

Schistosome Immunomics: High-Throughput Vaccine and Diagnostic Antigen Discovery

Schistosomiasis remains one of the highly prevalent and serious helminthiases in the countries of Asia, Africa and Latin America. Despite the accessibility of an effective drug against the fatal parasites, drug-based treatment projects still have certain limitations and it is likely that vaccine and effective diagnostic tools are essential for schistosomiasis control. Despite the several decade vaccine development has witnessed the finding and testing of couple of candidate targets, none have shown satisfactory protection. Upon the coming of genome era, it has revolutionized the study of the drug, vaccine, and immunodiagnosis, and also catalyzed a switch from traditional manual testing to automation operation.

Yang Guo, Bei Li, Xuzhi Ruan, Zongyun Chen and Jian Li*


Article Image 1

Vaccination Coverage and Sustaining Control of Measles in Africa: A Global Health Perspective

For over 50 years, a safe, effective and inexpensive vaccine has been in use but several challenges continue to hamper universal coverage and the sustained control of measles. Before the year 2000, measles was killing over 700,000 children each year worldwide of which 60% occurred in Sub-Saharan Africa [1]. Epidemiologic reports showed that although an estimated 15.6 million deaths had been prevented by measles vaccination between 2000 and 2013, progress has stalled and previous gains are being reversed [2]. Measles related deaths vary depending upon the average age of infection, the nutritional status of the population, measles coverage, HIV infection, vitamin A deficiency and access to health care [3]. The death rate due to measles is so high in Africa that, on average, a child dies every minute. To make the matter worse, every person with measles has a 90% chance of infecting people with whom they come into close contact, if they are unvaccinated [1]. Yet a single dose of measles vaccine is proven to be 93% effective at preventing disease in vulnerable populations exposed to the virus at a relatively low cost ($1 US dollar). The fact that many lives are still lost to this vaccine-preventable virus remains a key concern for global health.

Olivia G Mendel1 , Stephanie K King1 and Juliet N Sekandi2*


Article Image 1

Nanovaccine Delivery Systems in Vaccine Formulations

The important biological molecules such as polysaccharides, proteins, allergens and Pathogen Associated Molecular Patterns (PAMPs) are of nanometer in size. Hence, the size, charge, hydrophobic properties will influence their effects on the immune system by way of specific and varied response. Vaccines play a pivotal role in disease containment and prevention. One of the bottle necks is the vaccine administration system. Earlier vehicles and adjuvant systems pose unwanted reactions due to the nature of delivery system used in the vaccine. Delivery systems are those materials used for the administration of vaccines s in a controlled manner aimed to achieve a therapeutic effect. These systems provide: cell or tissue targeted delivery of the antigen, improved antigen presentation, solubility, sustained release and protection of the prophylactic agent from degradation.

Aruni Wilson1*


Article Image 1

Therapeutic Vaccination against Cancers - A Conceptual Overview with Updates on the Immunological Approach

Cancer immunotherapy has now finally made its way and entered a new era, after decades of intensive searching of a cure for the incurable. Current attentions are particularly drawn by the very promising outcomes from a series of experimental and clinical studies recently concluded [1], having tested and verified the “Immune Checkpoint Blockade” working hypothesis initially proposed by Dr. James Allison nearly 20 years ago [2]. The next central question is about how to extend or maximize the therapeutic and survival benefits for greater numbers of patients, and of different cancer types. This may be achieved by further identifications of new target checkpoint inhibitors, emphasizing more on the tumor-specific antigenic signals, and through combination with the therapeutic vaccination approach in particular. Here, by joining in the discussion, I intend to start with direct reference to various basic yet constantly evolving concepts based on which vaccination against neoplasm has been developed along, and now progressing towards.

Huang FP1*


Article Image 1

Evaluation of a Polyvalent Vaccine Obtained From Divergent Low Pathogenic H5N2 Isolates of the Avian Influenza Virus in Mexico

In Mexico, the strategy used for controlling the Avian Influenza Virus (AIV) involves the use of immunizations through an inactivated emulsion vaccine (H5N2), which protects birds from the disease. It has been shown that the strain used in this vaccine is phylogenetically distant from the strains that are isolated in the field. Therefore, the goal of this study was to prepare and evaluate a polyvalent vaccine with genetically divergent isolates of the low-pathogenicity H5N2 avian influenza virus strains that are prevalent in Mexico. A polyvalent vaccine (Poly-AI) was prepared using five isolates that exhibited phylogenetic divergence from the low-pathogenicity avian influenza H5N2 virus strains found in Mexico. Chickens were immunized with Poly-AI and challenged 28 days post-vaccination with two Low Pathogenic Avian Influenza Virus (LPAIV) isolates contained in the vaccine and one High Pathogenic Influenza Virus (HPAIV). Serology was done at different times and clinical signs were recorded. This is the first study that documents the degree of pathogenicity differences between various isolates that exhibit genetic variation in the nation. The experimental Poly-AI vaccine eliminated the clinical signs of the disease, demonstrated 100% protection against the challenge with a highly pathogenic strain and decreased excretion when challenged with homologous and high virulence strains, which was detected by qRT-PCR.

Elia Armas Bojórquez1 , Edith Rojas Anaya1 , Gary García Espinosa2 , Fernando Diosdado Vargas1 and Elizabeth Loza-Rubio1*